CR6086, AGEN2034 — catalyst calendar
Upcoming
| Date | Event | Company | Drug | Official source & verification |
|---|---|---|---|---|
| 2026-12 (month) in 2mo
ESTIMATED |
READOUT
Vorbipiprant (CR6086) / Balstilimab (AGEN2034) Combination in Stage IV Refractor
Phase 1/2 · Refractory Metastatic Colorectal Cancer, Solid Tumor |
Rottapharm Biotech | CR6086, AGEN2034 |
ClinicalTrials.gov ↗
✓ Source-checked 2026-09-20
Sponsor-projected date — can change
|